APC promoter hypermethylation is an early event in endometrial tumorigenesis

Cancer Science

Volumn 101, Issue 2, 2010, Pages 321-327

  Ignatov, Atanas ^a   Bischoff, Joachim ^a   Ignatov, Tanja ^a   Schwarzenau, Christa ^a   Krebs, Thomas ^a   Kuester, Doerthe ^a   Costa, Serban D ^a   Roessner, Albert ^a   Semczuk, Andrzej ^b   Schneider Stock, Regine ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DNA; KI 67 ANTIGEN; UVOMORULIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, APC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 75649143716     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01397.x     Document Type: Article

References (39)

1. Amant F, Moerman P, Neven P. Endometrial cancer. Lancet 2005, 366:491-505.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of " untreated" hyperplasia in 170 patients. Cancer 1985, 56:403-12.
3. Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979, 135:947-56.
4. Kendall BS, Ronnett BM, Isacson C. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998, 22:1012-9.
5. Mutter GL, Baak JP, Crum CP. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000, 190:462-9.
6. Deligdisch L, Kase NG, Bleiweiss IJ. Endometrial cancer in elderly women: a histologic and steroid receptor study. Gerontology 2000, 46:17-21.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-54.
8. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001, 10:721-33.
9. Behrens J, von Kries JP, Kuhl M. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382:638-42.
10. Fujimoto J, Ichigo S, Hori M. Expressions of E-cadherin and alpha- and beta-catenin mRNAs in uterine endometrial cancers. Eur J Gynaecol Oncol 1998, 19:78-81.
11. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999, 24:73-6.
12. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002, 38:867-71.
13. Gamallo C, Palacios J, Moreno G. beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999, 155:527-36.
14. Moreno-Bueno G, Hardisson D, Sanchez C. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002, 21:7981-90.
15. Sparks AB, Morin PJ, Vogelstein B. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998, 58:1130-4.
16. Stawerski P, Wagrowska-Danilewicz M, Stasikowska O. Immunoexpression of beta-catenin - E-cadherin complex in primary serous ovarian tumors. Pol J Pathol 2008, 59:27-32.
17. Esteller M, Corn PG, Baylin SB. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-9.
18. Virmani AK, Rathi A, Sathyanarayana UG. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001, 7:1998-2004.
19. Lambertz S, Ballhausen WG. Identification of an alternative 5′ untranslated region of the adenomatous polyposis coli gene. Hum Genet 1993, 90:650-2.
20. Zysman M, Saka A, Millar A. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002, 62:3663-6.
21. Banno K, Yanokura M, Susumu N. Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 2006, 16:1189-96.
22. Droufakou S, Deshmane V, Roylance R. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001, 92:404-8.
23. Kallakury BV, Sheehan CE, Winn-Deen E. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 2001, 92:2786-95.
24. Saito T, Nishimura M, Yamasaki H. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer 2003, 97:1002-9.
25. Pijnenborg JM, Kisters N, van Engeland M. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2004, 14:947-56.
26. Dong SM, Kim HS, Rha SH. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001, 7:1982-6.
27. Herman JG, Graff JR, Myohanen S. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-6.
28. Ignatov A, Bischoff J, Schwarzenau C. P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 2008, 111:365-71.
29. Cattoretti G, Becker MH, Key G. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168:357-63.
30. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182:311-22.
31. Semczuk A, Skomra D, Cybulski M. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem J 2001, 33:193-200.
32. Horree N, van Diest PJ, van der GP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008, 61:36-42.
33. Blechschmidt K, Kremmer E, Hollweck R. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 2007, 16:222-8.
34. Sakuragi N, Nishiya M, Ikeda K. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 1994, 53:183-9.
35. Scholten AN, Aliredjo R, Creutzberg CL. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 2006, 16:1379-85.
36. Gassel AM, Backe J, Krebs S. Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol 1998, 51:25-9.
37. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol 2007, 20:711-21.
38. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007, 23:413-8.
39. Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med 2007, 7:85-102.